StockNews.com Downgrades PDS Biotechnology (NASDAQ:PDSB) to Sell

PDS Biotechnology (NASDAQ:PDSB) was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Several other research analysts have also recently issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $21.00 price objective on shares of PDS Biotechnology in a research note on Thursday, October 24th. Alliance Global Partners upgraded PDS Biotechnology to a “strong-buy” rating in a report on Wednesday, August 21st. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $14.25.

PDS Biotechnology Stock Up 0.3 %

Shares of PDSB opened at $3.29 on Friday. The firm has a fifty day moving average price of $3.25 and a 200-day moving average price of $3.28. The company has a current ratio of 3.84, a quick ratio of 3.84 and a debt-to-equity ratio of 0.45. The firm has a market capitalization of $121.14 million, a P/E ratio of -2.70 and a beta of 1.93. PDS Biotechnology has a 12-month low of $2.53 and a 12-month high of $6.85.

PDS Biotechnology (NASDAQ:PDSB) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.08. During the same quarter in the previous year, the firm earned ($0.37) earnings per share. Equities research analysts expect that PDS Biotechnology will post -1.24 earnings per share for the current year.

Hedge Funds Weigh In On PDS Biotechnology

A number of hedge funds and other institutional investors have recently modified their holdings of PDSB. Vanguard Group Inc. raised its stake in PDS Biotechnology by 5.5% in the first quarter. Vanguard Group Inc. now owns 1,587,806 shares of the company’s stock worth $6,288,000 after buying an additional 82,135 shares in the last quarter. Blair William & Co. IL increased its holdings in shares of PDS Biotechnology by 204.4% in the 2nd quarter. Blair William & Co. IL now owns 121,743 shares of the company’s stock valued at $357,000 after acquiring an additional 81,743 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of PDS Biotechnology in the 2nd quarter worth $146,000. Squarepoint Ops LLC purchased a new stake in shares of PDS Biotechnology during the 2nd quarter worth $120,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in PDS Biotechnology during the second quarter valued at about $115,000. 26.84% of the stock is currently owned by institutional investors.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.